Last updated on April 2017

Dose-finding Study to Assess the Efficacy Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection


Brief description of study

The purpose of this study is to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.

Detailed Study Description

This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or placebo is given in addition to the local standard care.

Clinical Study Identifier: NCT02712983

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Bruxelles, Belgium
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Nice, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Neu Isenburg Hessen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Milan, Italy
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Barcelona, Spain
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Valencia, Spain
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Cambridge, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Penarth, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Dundee, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
London, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Newcastle-upon-Tyne, United Kingdom
  Connect »